| 货号 | 2711/1 |
| 供应商 | Tocris |
| 生物活性 | Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1agonists. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 计算分子量 | 3742.29 |
| 分子式 | C167H270N52O46 |
| 可溶性/溶解性 | Soluble to 2 mg/ml in water |
| CAS号 | 463930-25-8 |
| 序列号 | HSDAVFTDNYTRLRKQVAAKKYLQSIKNKR (Modifications: Tyr-31 = C-terminal amide) |
| 参考文献 | Temerozoet al (2013) Macrophage resistance to HIV-1 infection is enhanced by the neuropeptides VIP and PACAP. PLoS ONE 8 (6) 67701. PMID: 23818986. Panet al (2007) Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. J.Pharmacol.Exp.Ther. 320 900. PMID: 17110523. Clairmontet al (2006) Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. J.Med.Chem. 49 7545. PMID: 17149884. Tsutsumiet al (2002) A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51 1453. PMID: 11978642. |